MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2113-2120

  Wang, Li ^a   Mason, Kathy A ^a   Ang, K Kian ^a   Buchholz, Thomas ^a   Valdecanas, David ^a   Mathur, Anjili ^b   Buser Doepner, Carolyn ^b   Toniatti, Carlo ^b   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Lung and breast tumor xenografts; MK 4827; Poly (ADP ribose) inhibitor; Radiation

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIRAPARIB; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMANS; INDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875423694     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9770-x     Document Type: Article

References (35)

1. Chambon P, Weill JD, Mandel P (1963) Nicotinamide mononu-cleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11:39-43
2. Jagtap P, Szabo C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440
3. Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528
4. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B (2004) PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58:410-419
5. Plummer ER (2006) Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 6:364-368
6. Satoh MS, Lindahl T (1992) Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-358
7. Gerö D, Szabó C (2008) Poly(ADP-ribose) polymerase: a new therapeutic target? Curr Opin Anaesthesiol 21:111-121
8. Durkacz BW, Omidiji O, Gray DA, Shall S (1980) (ADP-ribose)n participates in DNA excision repair. Nature 283 (5747):593-596
9. Shieh WM, Ame JC, Wilson MV, Wang ZQ, Koh DW, Jacobson MK, Jacobson EL (1998) Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem 273:30069-30072
10. Clark JB, Ferris GM, Pinder S (1971) Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim Biophys Acta 238:82-85
11. Underhill C, Toulmonde M, Bonnefoi H (2010) A review of PARP inhibitors: from bench to bedside. Ann Oncol 22(2):268-279
12. Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7(4):1-20
13. Zaremba T, Curtin NJ (2007) PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 7:515-523
14. Comen EA, Robson M (2010) Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 24(1):55-62
15. Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA (2004) Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205 (2):155-160
16. Mason KA, Valdecanas D, Hunter NR, Milas L (2008) INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Invest New Drugs 26(1):1-5
17. Telli ML, Ford JM (2010) PARP Inhibitors in Breast Cancer. Clin Adv Hematol Oncol 8(9):629-635
18. Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ (2009) PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases. Free Radic Biol Med 47(1):13-26
19. Lewis C, Low JA (2007) Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Curr Opin Investig Drugs 8 (12):1051-1056
20. Southan GJ, Szabó C (2003) Inhibitors of poly(ADP-ribose) polymerase. Curr Med Chem 10(4):321-340
21. Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V (2006) Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1, 8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 5(3):564-574
22. Donawho CK, Luo Y, Luo Y, Penning TD et al (2007) ABT-888, an orallyactive poly(ADP-Ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13(9):2728-2737
23. Calabrese CR, Almassy R, Barton S et al (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96 (1):56-67
24. Dungey FA, Caldecott KW, Chalmers AJ (2009) Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol Cancer Ther 8(8):2243-2254
25. Khan K, Araki K, Wang D et al (2010) Head and neck cancer radiosensitization by the novel poly (ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 32(3):381-391
26. Russo AL, Kwon HC, Burgan WE et al (2009) In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-Ribose) polymerase inhibitor E7016. Clin Cancer Res 15(2):607-612
27. Albert JM, Cao C, Kim KW et al (2007) Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13(10):3033-3042
28. Efimova EV, Mauceri HJ, Golden DW et al (2010) Poly(ADP-Ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70 (15):6277-6282
29. Thomas HD, Calabrese CR, Batey MA et al (2007) Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 6(3):945-956
30. Dungey FA, Löser DA, Chalmers AJ (2008) Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72(4):1188-1197
31. Jones P, Altamura S, Boueres J et al (2009) Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem 52 (22):7170-7185
32. Penning TD (2010) Small-molecule PARP modulators-current status and future therapeutic potential. Curr Opin Drug Discov Devel 13(5):577-578
33. Sandhu S, Wenham R, Wilding G, McFadden M, Sun L, Toniatti C, Stroh M, Carpenter C, De Bono J, Schelman W (2010) First-inhuman trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. ASCO Annual Meeting, Chicago, IL, USA (2010):Abs 3001
34. Ménissier de Murcia J, Ricoul M, Tartier L et al (2003) Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 22:2255-2263
35. Powell C, Mikropoulos C, Kaye SB, Nutting CM, Bhide SA, Newbold K, Harrington KJ (2010) Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev 36(7):566-575